PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17932766-0	2008	Captopril and lisinopril decrease acetaldehyde effects upon the prothrombin time.	Lisinopril	14-24	coagulation factor II, thrombin	Homo sapiens	64-75	
17932766-1	2008	Captopril, a thiol-containing antihypertensive drug, and lisinopril, an amino-containing antihypertensive drug, will both prolong the prothrombin time (PT) of Level I plasma.	Lisinopril	57-67	coagulation factor II, thrombin	Homo sapiens	134-145	
8165541-0	1994	Both lisinopril and verapamil reduced platelet-derived growth factor-A chain mRNA levels in human saphenous vein endothelial cells stimulated by thrombin.	Lisinopril	5-15	coagulation factor II, thrombin	Homo sapiens	145-153	
8165541-6	1994	PDGF-AA homodimer in conditioned media was measured by ELISA: RESULTS: Lisinopril attenuated the induction by thrombin of PDGF-A chain mRNA levels significantly in human ECs at doses of 10(-6) mol/L and 10(-5) mol/L (p < 0.05) and appeared to decrease PDGF-AA homodimer released in conditioned medium.	Lisinopril	71-81	coagulation factor II, thrombin	Homo sapiens	110-118	
8165541-8	1994	CONCLUSIONS: These data suggest that one means by which lisinopril and verapamil both suppress intimal thickening might be inhibition of PDGF-A chain gene expression in ECs regrowing over vessel injury areas that are sites of thrombin generation.	Lisinopril	56-66	coagulation factor II, thrombin	Homo sapiens	226-234	
2172073-3	1990	Continuation of lisinopril administration for 3 weeks after the onset of jaundice was associated with the development of grade III encephalopathy and a marked decrease in prothrombin and proaccelerin levels.	Lisinopril	16-26	coagulation factor II, thrombin	Homo sapiens	171-182